Catalyst Pharmaceuticals Inc
Research Catalyst Pharmaceuticals Inc (CPRX) on Bullrun: valuation model: 5.4% undervalued, market cap USD 3.85B, P/E 18.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCPRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal5.4% undervalued
- Market capUSD 3.85B
- P/E18.1
- Financial periodFY2025
- RevenueUSD 588.99M
- Revenue growth19.8%
- Net incomeUSD 214.33M
- Free cash flowUSD 208.61M
- Gross margin85.2%
Valuation Snapshot
Bullrun's latest valuation model marks Catalyst Pharmaceuticals Inc as 5.4% undervalued; latest market cap is USD 3.85B; P/E is 18.1.
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS);
Frequently asked questions
Is Catalyst Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks Catalyst Pharmaceuticals Inc as 5.4% undervalued.
What is Catalyst Pharmaceuticals Inc's market cap?
Catalyst Pharmaceuticals Inc's market capitalization is USD 3.85B.
What is Catalyst Pharmaceuticals Inc's P/E ratio?
Catalyst Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 18.1.
What does Catalyst Pharmaceuticals Inc do?
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS);